Table 4 Summary of relative risk (95% CI excluding one) of adverse events occurring in ≥10% of patients in either of the treatment arms (Chinese safety population)
Relative risk (pazopanib/sunitinib) | |||||
|---|---|---|---|---|---|
Preferred term | Pazopanib (N = 109) | Sunitinib (N = 100) | Ratio | 95% CI | P value |
Skin hypopigmentation | 13 (12) | 3 (3) | 3.98 | (1.167–13.543) | 0.0270 |
Hair color changes | 47 (43) | 13 (13) | 3.32 | (1.912–5.755) | < 0.001 |
Diarrhea | 57 (52) | 37 (37) | 1.41 | (1.034–1.932) | 0.0309 |
Blood creatinine increased | 21 (19) | 32 (32) | 0.60 | (0.373–0.972) | 0.0362 |
Neutrophil count decreased | 25 (23) | 40 (40) | 0.57 | (0.377–0.872) | 0.0086 |
Platelet count decreased | 23 (21) | 39 (39) | 0.54 | (0.349–0.838) | 0.0059 |
Eyelid edema | 16 (15) | 28 (28) | 0.52 | (0.302–0.910) | 0.0200 |
Thrombocytopenia | 20 (18) | 39 (39) | 0.47 | (0.295–0.750) | 0.0016 |
White blood cell count decreased | 17 (16) | 33 (33) | 0.47 | (0.281–0.794) | 0.0044 |
Blood lactate dehydrogenase increased | 9 (8) | 18 (18) | 0.46 | (0.216–0.974) | 0.0429 |
Blood thyroid stimulating hormone increased | 8 (7) | 19 (19) | 0.39 | (0.177–0.843) | 0.0179 |
Peripheral edema | 6 (6) | 14 (14) | 0.39 | (0.157–0.984) | 0.0440 |
Hemoglobin decreased | 13 (12) | 31 (31) | 0.38 | (0.214–0.693) | 0.0013 |
Stomatitis | 4 (4) | 12 (12) | 0.31 | (0.102–0.917) | 0.0362 |
Anemia | 7 (6) | 25 (25) | 0.26 | (0.116–0.568) | < 0.001 |
Nasopharyngitis | 2 (2) | 10 (10) | 0.18 | (0.041–0.817) | 0.0244 |
Facial edema | 3 (3) | 17 (17) | 0.16 | (0.049–0.536) | 0.0052 |
Yellow skin | 3 (3) | 22 (22) | 0.13 | (0.039–0.405) | < 0.001 |
Xanthochromia | 1 (< 1) | 10 (10) | 0.09 | (0.012–0.704) | 0.0203 |